A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: John M. Maris Frank Balis Susan L. Cohn |
| Publication date | August 1, 2006 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |